AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$FTRE

Russell Carrie Elizabeth sold $4K of FTRE

Russell Carrie Elizabeth (Interim CAO) sold 246 shares of Fortrea Holdings Inc. (FTRE) at $16.85 on 2026-09-09.

Original reporting
SEC EDGAR · Russell Carrie Elizabeth
Published Sep 10, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
high confidence
Mentioned
$FTRE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The disclosed sale is modest and does not suggest a change in insider confidence.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions not yet announced could contextualize the sale.

Relevance 3/10Novelty 3/10Timing: filed Sep 10 2026

Background

Form 4 filings disclose insider transactions; investors track them for signals of confidence.

Company-level read

Ticker impact

$FTRENeutralHigh confidence
Context

Officer Russell Carrie Elizabeth sold 246 shares of Fortrea Holdings for $4,145, a direct insider sale disclosed via Form 4.

Expected impact

No significant price movement expected.

Evidence & confidence

The sale size is small relative to total shares and typical for insiders; market impact is negligible.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sales sometimes precede negative news; monitor for upcoming disclosures.

Key entities

  • Company
    Fortrea Holdings Inc.

    US-listed biotech firm (ticker FTRE).

  • Insider
    Russell Carrie Elizabeth

    Interim Chief Accounting Officer of Fortrea.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FTRE insider trading history →

Related articles

SEP 2
$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

financialcontent.com2 min
SEP 2
$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

rttnews.com2 min
SEP 2
$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

finanznachrichten.de2 min